Novartis Shares Jump as MS Drug Triumph Overshadows Cell Therapy Setback
Published on 09/02/2026 at 03:22 | Editorial boerse-global.de
Investors in the Swiss pharma giant got a two-sided story on Tuesday, and they voted decisively with their wallets. Novartis shares surged 5.3 percent in Zurich trading after the company unveiled late-stage data showing its BTK inhibitor Remibrutinib significantly outperformed a rival therapy in relapsing multiple sclerosis — even as the group simultaneously disclosed a safety halt across eight clinical trials of its experimental cell therapy.
The market's reaction suggests traders are willing to look past the cell therapy troubles for now. The stock settled at €138.64, having climbed roughly 2.6 percent above its 50-day moving average of €135.06, with the shares up 17 percent since the start of the year and trading near a 52-week high of €144.30.
Remibrutinib Delivers on Two Fronts
The headline numbers came from the Phase III REMODEL-1 and REMODEL-2 studies, which tested Remibrutinib against Sanofi's Aubagio (teriflunomide) in roughly 2,000 patients with relapsing MS. The drug hit its primary endpoint, delivering a statistically significant reduction in annualized relapse rates, and also showed superiority on inflammatory brain lesions and key secondary measures. No liver safety signal emerged from the trials.
The company plans to file for regulatory approvals worldwide following a full data presentation at the MS Toronto congress in October. Remibrutinib already has commercial traction: the FDA approved it for chronic spontaneous urticaria in September 2025, with the European Medicines Agency following suit in April 2026.
A Setback in the Cell Therapy Pipeline
The same day brought sobering news from the cell therapy front. Novartis confirmed it had paused eight clinical studies of Rap-Cel, its experimental CAR-T therapy being developed for autoimmune conditions including lupus, rheumatoid arthritis, and myasthenia gravis. The decision followed the deaths of three patients from severe immune reactions known as IEC-HS. Oncology studies using Rap-Cel are continuing unchanged, and the company has launched a comprehensive safety review with independent committees. Bristol-Myers Squibb has also temporarily paused a similar program as a precaution.
When serious safety concerns emerge in clinical trials, it's a reminder that rigorous risk assessment matters in every setting — including the workplace. Many employers underestimate the dangerous gaps in their health and safety documentation. A free toolkit with 41 ready-to-use checklists and templates helps you identify and document workplace risks properly, keeping your team protected and your business compliant. Download the free Risk Assessment Toolkit
Competition Heats Up in MS
The bullish case for Remibrutinib rests on more than just these two trials. It is the first BTK inhibitor to succeed in two Phase III studies, a notable distinction in a field where Roche's Fenebrutinib and Sanofi's Frexalimab have also posted positive late-stage results. The competitive landscape is tightening, and the full picture won't be clear until the complete dataset is peer-reviewed and presented in Toronto.
William Blair analysts have pointed to the intensifying rivalry in the MS market as a factor to watch. The question for investors is whether Remibrutinib can carve out a meaningful share against both established treatments and the incoming wave of competitors — and whether the current valuation, near its yearly peak, already prices in that success.
A Solid Foundation Beneath the Rally
The clinical momentum sits atop a sturdy operational base. Novartis reported second-quarter revenue of 78.49 billion Danish kroner with operating profit up 11 percent, supported in part by Entresto, whose patent protection was upheld by a British court through 2028. A successful Remibrutinib launch would add another growth pillar to that foundation.
The company also noted an expansion of Pluvicto's indications in radioligand therapy roughly three weeks ago, adding to the positive pipeline narrative. Meanwhile, the broader biotech sector has seen a pickup in dealmaking, with transaction volumes reaching around $130 billion in the first half of 2026, according to media reports — an environment that some read as validating Novartis's research capabilities.
What Could Derail the Rally
The bear case centers on two vulnerabilities. First, the Rap-Cel halt raises questions about the safety profile of Novartis's cell therapy platform. Three deaths from severe immune reactions is a serious signal, and the ongoing review could lead to further restrictions or even discontinuation of some autoimmune indications. While the oncology arm remains unaffected, reputational damage to the broader cell therapy franchise cannot be ruled out.
Second, the Remibrutinib results are still topline data. Until the full analysis is presented and scrutinized, the current share price rests on preliminary findings rather than peer-reviewed outcomes. If the detailed results show weaker efficacy relative to Frexalimab or Fenebrutinib, some of the recent gains could evaporate.
The Road Ahead
The next concrete milestone is the complete data presentation at the MS Toronto congress from October 21 to 23, followed by the planned global regulatory submissions. As long as the Rap-Cel safety review produces no additional negative findings and the Remibrutinib data holds up under scrutiny, the positive trajectory appears intact. A deterioration on either front — expanded safety concerns in cell therapy or disappointing detail data on Remibrutinib — would likely trigger a pullback from current levels.
